CJC – 1295 DAC (5 MG)

(3 customer reviews)


Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol

Growth hormone releasing hormone (GHRH) has been altered a number of times to produce analogues that prevent some of the hormone’s effects while eliminating others. One of those modifications, CJC-1295, consists of just the first 29 amino acids of GHRH. This analogue of GHRH, which is technically a maleimide derivative of hGRF(1-29), was created in an effort to produce a more soluble GH secretagogue that is easier to produce in large quantities but still preserves the core competencies of GHRH.


CJC-1295 Versus CJC-1295 DAC

CJC-1295 is an altered version of the first 29 amino acids of GHRH, which means it is chemically like other GHRH analogues, like Sermorelin. It is most like modified GRF (1-29), but the two peptides are not identical. A great deal of confusion arises due to the similarities between these peptides and with the origin of CJC-1295 as an added chemical compound known as the drug affinity complex abbreviated as DAC. DAC is added to the molecule, with the help of a lysine linker, to safeguard the peptide while it circulates in the blood stream. By allowing peptides to bind to the common blood protein albumin, DAC helps to ensure that the half-life of CJC-1295 is much longer than similar molecules like GRF (1-29).

Originally, ConjuChem Biotechnologies, the developer of DAC, referred to the molecule containing DAC as simply CJC-1295. Confusion arose, nonetheless, because the peptide was also being offered without DAC. To avoid confusion, CJC-1295 that contains DAC is called CJC-1295-DAC and when it does not contain DAC it is referred to as CJC-1295 or CJC-1295-no DAC.

CJC-1295 Research

CJC-1295 and Growth Hormone Release. As a derivative of GHRH, it should come as no brainer that CJC-1295 aggravates the release of growth hormone. Studies show that a single dose of CJC- 1295 increase GH levels in mice by 2-10 times. Peak GH levels are reached approximately 2 hours after administration, and the effects last for nearly six days. Unlike other GH secretagogues, CJC-1295 preserves normal physiologic release of GH[1]. That means that the normal circadian peaks and valleys seen in GH release remain intact and that CJC-1295 is a physiologic growth hormone releasing factor. Preserving physiologic release of GH even while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects. Specifically, CJC-1295 has been shown to preserve the physiologic effects of growth hormone’s on hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and myocardial (heart cell) function.

CJC-1295 and Growth

Studies in mice without normal GHRH physiology have shown that CJC-1295 preserves normal GH release[2]. This makes the peptide potentially useful as a therapy for abnormal growth in a variety of mammalian species, humans included. Preserving normal pulsatile release of GH is critical to ensuring that proper release of downstream hormones, such as insulin-life growth factor-2 (IGF-1).

CJC-1295 and Infertility

Research from the early 1990s suggests that CJC-1295 and other GRF analogues may be useful in promoting ovulation in infertile female patients. Scientists have long known that ovulation is dependent on IGF-1 and that it is also likely influenced by GH release and cycling. Research in animal models of superovulation has helped to confirm these theories by showing that both GH and IGF-1 levels rise significantly surrounding the time of ovulation. Further, these studies indicate that exogenous administration of GH secretagogues, like CJC-1295, is enough to cause appropriate ovulation[3]. There is some speculation that CJC-1295 and other analogues may even be useful in male infertility by helping to regulate sperm production. This latter hypothesis has yet to be tested.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories.

Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between PeptidesforSale.com and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [4] under the referenced citations.

Referenced Citations

[1] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. [PubMed]

[2] M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]

[3] A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991. [PubMed]

[4] Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]

3 reviews for CJC – 1295 DAC (5 MG)

  1. Dr. Mclaughlin

    Very professional company to work with. Best DAC I have ever found with any online research peptides seller

  2. Michael Smith

    “Impressive research results! Our lab has observed increased energy levels and improved recovery in our test subjects. We’ll definitely continue using CJC-1295 DAC for our studies.”

  3. Dr Strauss

    Awesome experience with the product. Highly recommended when it comes to research peptides

Add a review

Your email address will not be published. Required fields are marked *

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.